scholarly journals The Burden of Hepatitis C Infection–Related Liver Fibrosis in the United States

2016 ◽  
Vol 63 (8) ◽  
pp. 1049-1055 ◽  
Author(s):  
R. Monina Klevens ◽  
Lauren Canary ◽  
Xiaohua Huang ◽  
Maxine M. Denniston ◽  
Anthony E. Yeo ◽  
...  
Keyword(s):  
United States ◽  
Hepatitis C ◽  
Liver Fibrosis ◽  
The United States ◽  
Hepatitis C Infection

Cost-effectiveness of combination daclatasvir-sofosbuvir for treatment of genotype 3 chronic hepatitis C infection in the United States

2017 ◽  
Vol 20 (7) ◽  
pp. 692-702 ◽  
Author(s):  
Catherine Saint-Laurent Thibault ◽  
Divya Moorjaney ◽  
Michael L. Ganz ◽  
Bruce Sill ◽  
Shalini Hede ◽  
...  
Keyword(s):  
United States ◽  
Chronic Hepatitis ◽  
Cost Effectiveness ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
The United States ◽  
Hepatitis C Infection ◽  
Genotype 3

Retrospective Analysis of the Medication Utilization and Clinical Outcomes of Patients Treated with Various Regimens for Hepatitis C Infection

2016 ◽  
Vol 30 (2) ◽  
pp. 154-161 ◽  
Author(s):  
William D. Trombatt ◽  
Pamela H. Koerner ◽  
Zoie N. Craft ◽  
Richard T. Miller ◽  
Khalid M. Kamal
Keyword(s):  
United States ◽  
Hepatitis C ◽  
Adverse Events ◽  
Clinical Outcomes ◽  
The United States ◽  
Virologic Response ◽  
Phase Iii ◽  
Hepatitis C Infection ◽  
Medication Utilization ◽  
Patient Reported

Background: The hepatitis C virus (HCV) is the most common chronic blood-borne infection and the leading cause of liver transplantation in the United States. There are approximately 3.2 million people currently infected with HCV in the United States. In late 2013, the introduction of sofosbuvir and simeprevir represented a critical advancement in the treatment of HCV by improving sustained virologic response (SVR) rates. Purpose: The purpose of this study was to evaluate medication utilization and clinical outcomes of patients with HCV who were treated with any Food and Drug Administration-approved combination of ribavirin, peginterferon products, simeprevir, and sofosbuvir. Methods: Prescription records and clinical assessment forms of patients who started HCV therapy and were eligible for SVR between January 1, 2014, and December 31, 2014, were retrospectively reviewed. Data collection included patient demographics, genotype, SVR, patient-reported adverse events, discontinuations, and adherence markers. Results: A total of 367 eligible patients were identified who had initiated treatment during the study period. Genotype 1 was the most common genotype, and an overall SVR rate of 86.9% was observed. Results were similar to those seen in phase III clinical trials. In addition, adverse events of these medications were more tolerable, and discontinuation rates were lower than with previous therapies.

Humanistic and economic impacts of hepatitis C infection in the United States

2010 ◽  
Vol 13 (4) ◽  
pp. 709-718 ◽  
Author(s):  
Marco daCosta DiBonaventura ◽  
Jan-Samuel Wagner ◽  
Yong Yuan ◽  
Gilbert L'Italien ◽  
Paul Langley ◽  
...  
Keyword(s):  
United States ◽  
Hepatitis C ◽  
Economic Impacts ◽  
The United States ◽  
Hepatitis C Infection

Hepatitis C Infection Screening and Management in Opioid Use Epidemics in the United States

2018 ◽  
Vol 131 (11) ◽  
pp. 1276-1278 ◽  
Author(s):  
Xibei Liu ◽  
Jay Shen ◽  
Pearl Kim ◽  
Seong-min Park ◽  
Sungyoun Chun ◽  
...  
Keyword(s):  
United States ◽  
Hepatitis C ◽  
The United States ◽  
Opioid Use ◽  
Hepatitis C Infection

Hepatitis C Infection Screening and Management in Opioid Use Epidemic in the United States

2018 ◽  
Vol 113 (Supplement) ◽  
pp. S1591-S1592
Author(s):  
Annie S. Hong ◽  
Syed M. Saghir ◽  
Ji Won Yoo ◽  
Mohamed Azab
Keyword(s):  
United States ◽  
Hepatitis C ◽  
The United States ◽  
Opioid Use ◽  
Hepatitis C Infection
Sign in / Sign up

Export Citation Format

Share Document